The demand for Lipid-Lowering Agents in Oman has been steadily increasing over the past few years, driven by a growing awareness of the health risks associated with high cholesterol levels.
Customer preferences: As in many other countries, patients in Oman prefer to use statins, which are the most commonly prescribed type of Lipid-Lowering Agents. This is due to their proven efficacy in reducing cholesterol levels and preventing cardiovascular disease. Patients also prefer to use generic versions of these drugs, as they are more affordable and widely available.
Trends in the market: One of the key trends in the Lipid-Lowering Agents market in Oman is the increasing availability of combination therapies. These drugs combine different types of Lipid-Lowering Agents, such as statins and fibrates, to provide a more comprehensive approach to cholesterol management. Another trend is the growing use of non-statin drugs, such as PCSK9 inhibitors, which are used in patients who cannot tolerate statins or who require additional cholesterol-lowering therapy.
Local special circumstances: One of the unique features of the Lipid-Lowering Agents market in Oman is the high prevalence of obesity and diabetes among the population. This has led to a greater demand for Lipid-Lowering Agents, as these conditions are closely linked to high cholesterol levels. Additionally, the government of Oman has implemented several initiatives aimed at promoting healthy lifestyles and reducing the incidence of chronic diseases, which has helped to raise awareness of the importance of cholesterol management.
Underlying macroeconomic factors: The Lipid-Lowering Agents market in Oman is also influenced by broader macroeconomic factors, such as the country's economic growth and healthcare expenditure. Oman has experienced steady economic growth in recent years, which has led to an increase in healthcare spending. This has enabled the government to invest in healthcare infrastructure and to provide greater access to essential medicines, including Lipid-Lowering Agents. Additionally, the increasing prevalence of chronic diseases in Oman has put pressure on the healthcare system to provide effective and affordable treatments, which has further boosted demand for Lipid-Lowering Agents.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
